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ProfileBrave Pioneers or Clinical Cowboys?As some stem cell researchers move
ahead with clinical trials of new therapies,
they’re facing criticism from others in the
field who argue the transition is prema-
ture. Tensions between the two factions
have been intensified by the spotlight of
political controversy and media attention,
triggering heated debates in the pages of
journals and at meetings.
‘‘People have very firm viewpoints on
this,’’ says Joshua Hare, a cardiologist
and director of the Interdisciplinary Stem
Cell Institute at the University of Miami’s
Miller School of Medicine. ‘‘There are
different schools of thought because
people perceive the stakes as so high.’’
Among researchers investigating poten-
tial cardiac therapies based on adult stem
cells–currently one of the more contentious
areas of research–‘‘There’s a huge spec-
trumofskepticismandconcern,andenthu-
siasm,’’ according to Richard Cannon,
a cardiologist at the National Heart, Lung,
and Blood Institute (NHLBI). ‘‘I don’t think
I’m overstating the tension there isbetween
basic scientists and clinical investigators,
at least in some quarters.’’
George Daley, a hematologist and
director of the Stem Cell Transplantation
Program at Children’s Hospital Boston,
attributes that largely to ‘‘a clash of
cultures’’ between basic scientists and
clinical investigators. Hare, who has
begun clinical trials using bone marrow-
derived stem cells to treat heart disease,
agrees, saying, ‘‘Someone who sees
patients and treats patients is going to
be much more comfortable taking these
therapies into trials, particularly in settings
with major unmet needs.’’
The debate flared up at the NHLBI’s
third Symposium on Cardiovascular
Regenerative Medicine late last year
where clinical investigators were the
targets of criticism during a panel discus-
sion. Cannon, who is investigating the
potential of bone marrow-derived stem
cells to repair diseased and damaged
blood vessels in patients with coronary
artery disease, says, ‘‘We were pretty
much taken to task for endorsing or per-
forming clinical research without knowing
everything there is to know about the
mechanism of cell-based approaches to
heart disease.’’504 Cell Stem Cell 6, June 4, 2010 ª2010 ElsClinical investigators, Daley says, ‘‘are
much more tolerant of uncertainties in
mechanism, whereas ‘‘arguably the
greatest insight into mechanism comes
from the stem cell scientific community,’’
he adds. ‘‘I think that’s where cultural
wars will be fought.’’
Daley describes himself as ‘‘fairly
conservative’’ on the matter of when it’s
appropriate to begin clinical trials of adult
stem cell therapies. Understanding the
mechanism of action isn’t an absolute
prerequisite, he says, but if it’s not
clear, ‘‘that does have to give one extra
pause’’ if there’s even a plausible risk to
patients.
Nonetheless, Daley says he has ‘‘a
healthy respect for the value of pure
empiricism in medical innovation.’’
Many therapies that are commonly used
today, Hare points out, were administered
to patients for years before researchers
understood their mechanism of action.
When bone marrow transplants were first
performed, for example, no one really
knew how they worked. Plenty of other
invaluable therapies, such as lithium,
which has long been the standard treat-
ment for bipolar disorder, remain largely
a mystery in terms of their mechanism.
‘‘If a patient had a problem,’’ Hare says,
‘‘and there was a proven treatment, but
we didn’t know the mechanism, most
treating physicians would use it.’’
Martin Friedlander, a cell biologist and
ophthalmologist at Scripps Clinic and
The Scripps Research Institute, says,
‘‘I’m not so hung up on the mechanism
thing, I’m hung up on the safety thing.’’
In particular, says Friedlander, who is
investigating the use of adult stem cells
to treat vision loss, but hasn’t tested the
approach in clinical trials, researchers
should know exactly what kind of cells
are being administered, and understand
how they may behave, before testing
them in humans.
‘‘If there’s evidence from large animal
models that the cells do something benefi-
cial, even if you don’t know exactly how
they accomplish that, and as long as
there’s no suspicion harm, I think it’s
reasonable to take those cells into trials
in patients with potentially life-threatening
heart disease,’’ Cannon says.evier Inc.‘‘There’s only so much you can learn
about what cells can do and can’t do,’’
from animal studies, Cannon adds.
‘‘The field is bound to move forward
prior to us having a really good sense of
the range of risks and rewards,’’ Daley
says. ‘‘This is something that is seen
with any new medical technology. There’s
nothing new with stem cells other than
them having attracted a lot of attention.’’
Unfortunately, Daley adds, the attention
that’s been paid to stem cells and their
therapeutic potential—largely because
of the political controversy over human
embryonic stem cell research—has fu-
eled medical profiteers.
There are advertisements all over the
Internet from clinicsaround the world, tout-
ingstemcell treatments for everything from
spinal cord injuries to autism to cancer.
‘‘It’s unethical, and in the United States, it
would be illegal,’’ Friedlander says.
The therapies on offer at these rogue
clinics may be pointless, or potentially
dangerous, but there are plenty of people
facing the prospect of losing their vision or
living the rest of their life in a wheelchair,
who are prepared to take that chance.
‘‘There’s so little being offered in the
United States that people are leaving,’’
says Hare, who sees that as all the more
reason to proceed with clinical trials of
potential stem cell therapies. He’d like to
see a clinic set up in the United States to
do ‘‘aggressive translational work, so
that these poor people can get therapy
ethically, rigorously, and with proper
monitoring, and they can get the best
therapy available. These programs need
to be under FDA-approved research
protocols so we can learn and optimize
the approaches.’’
Daley worries that all the attention
that’s been paid to potential stem cell
therapies has not only created an oppor-
tunity for medical profiteers, it’s also
generated tremendous optimism that
can all too easily veer into wishful thinking.
‘‘There are some people out there who
think they know more than they do,’’
Daley says.
‘‘It’s like anything else. You’re always
going to have cowboys and cowgirls who
are out there doing stuff before every-
one else,’’ Friedlander adds. ‘‘You’ve got
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Profilethese predators who are looking to make
a quick dollar, and then there are clini-
cians who are well-meaning but relatively
uninformed about how to use these cells,’’
Friedlander says.
‘‘It’s pretty easy for professionals in the
[stem cell] community to look at some of
these and recognize what’s beyond the
pale, but there’s a huge gray area,’’ of
work that’s well intentioned but mis-
guided, Daley says. He regards cardiac
stem cell therapies as a prime example of
clinical studies that are advancing without
an adequate understanding of mecha-
nism, ‘‘There are a lot of stem cell biolo-
gists who believe they are an enormous
waste of resources.’’
The criticism irks Hare, who is conduct-
ing Phase II trials using bone marrow stem
cells, administered intravenously, to treat
patients after heart attacks.
‘‘We’ve done everything right. We
should be beyond criticism,’’ Hare says.
‘‘It’s hard to understand why people stand
up and say, ‘You’ve gone too far.’ The
arguments against moving into the clinic
go against conventional wisdom. We’re
following basic principles of therapeutic
development,’’ Hare adds. ‘‘No one would
have questioned this if we were devel-
oping a drug.’’Cannon says some of the discomfort
over stem cell-based approaches to the
treatment of heart disease may be
because ‘‘we’re talking about a very new
approach.’’ While hematologists have
been using cell-based therapies for
decades, for cardiologists, ‘‘this is a new
paradigm,’’ he says.
Friedlander worries that some
researchers ‘‘may not have a clear under-
standing of how much damage you can
do with an approach that hasn’t been
thoroughly vetted. If someone jumps the
gun and there’s a setback that’s serious,’’
he adds, ‘‘that puts the whole field back.’’
Gene therapy is a case in point. It was
hailed as a potential medical revolution
during the 1980s, but later clinical trials
yielded disappointing, and in a few cases,
tragic, results, although Hare says, ‘‘We
learned something really important—that
it had unanticipated toxicity.’’
Daley says those trials were premature
and researchers had yet to learn how
hard it would be to achieve gene transfer.
That’s a good lesson for the stem cell
field, he says. ‘‘We’ve not yet faced the
sobering reality of how difficult it’s going
to be.’’
It won’t be easy, either, to achieve an
armistice among stem cell researchers.Cell Stem CThose on the frontlines agree, though,
that rather than letting the two sides
huddle in their trenches, emerging only
occasionally to face each other in battle,
it’s essential to get the warring factions
engaged in productive discussions.
‘‘We need to get basic scientists and
clinical researchers in the room together
so they can talk about their motivations
and views and experiences,’’ Cannon
says, ‘‘so hopefully the field moves
forward.’’ The NHLBI aims to accomplish
that via its Progenitor Cell Biology
Consortium, established last fall.
It’s also a goal of the ISSCR, says Da-
ley, who was president of the society
from 2007–2008 and led the ISSCR task-
force that developed guidelines for
human embryonic stem research.
‘‘We’re trying to create opportunities to
bring those two communities together.’’
‘‘It should be a partnership,’’ Cannon
says. ‘‘Clinical trials should proceed
along with basic research. It’s not an
either-or situation.’’ After all, he adds,
there’s a good dose of mystery in medi-
cine. ‘‘To wait to understand everything
about these cells may delay the poten-
tial they have for therapeutic use.
There’s an unknown, and perhaps an
unknowable.’’Anna C. Davison
Santa Barbara, CA, USA
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